169 related articles for article (PubMed ID: 15367708)
1. Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs.
Don S; Verrills NM; Liaw TY; Liu ML; Norris MD; Haber M; Kavallaris M
Mol Cancer Ther; 2004 Sep; 3(9):1137-46. PubMed ID: 15367708
[TBL] [Abstract][Full Text] [Related]
2. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells.
Kavallaris M; Tait AS; Walsh BJ; He L; Horwitz SB; Norris MD; Haber M
Cancer Res; 2001 Aug; 61(15):5803-9. PubMed ID: 11479219
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation.
Martello LA; Verdier-Pinard P; Shen HJ; He L; Torres K; Orr GA; Horwitz SB
Cancer Res; 2003 Mar; 63(6):1207-13. PubMed ID: 12649178
[TBL] [Abstract][Full Text] [Related]
4. Parkin binds to alpha/beta tubulin and increases their ubiquitination and degradation.
Ren Y; Zhao J; Feng J
J Neurosci; 2003 Apr; 23(8):3316-24. PubMed ID: 12716939
[TBL] [Abstract][Full Text] [Related]
5. Identification of a new microtubule-interacting protein Mip-90.
González M; Cambiazo V; Maccioni RB
Eur J Cell Biol; 1995 Jun; 67(2):158-69. PubMed ID: 7664757
[TBL] [Abstract][Full Text] [Related]
6. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
Poruchynsky MS; Kim JH; Nogales E; Annable T; Loganzo F; Greenberger LM; Sackett DL; Fojo T
Biochemistry; 2004 Nov; 43(44):13944-54. PubMed ID: 15518543
[TBL] [Abstract][Full Text] [Related]
7. The C-terminus of stathmin-like proteins governs the stability of their complexes with tubulin.
Campanacci V; Gigant B
Biochem Biophys Res Commun; 2023 Nov; 682():244-249. PubMed ID: 37826947
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
9. New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies.
Wilson L; Jordan MA
J Chemother; 2004 Nov; 16 Suppl 4():83-5. PubMed ID: 15688618
[TBL] [Abstract][Full Text] [Related]
10. Enhanced stability of microtubules contributes in the development of colchicine resistance in MCF-7 cells.
Rai A; Kapoor S; Naaz A; Kumar Santra M; Panda D
Biochem Pharmacol; 2017 May; 132():38-47. PubMed ID: 28242250
[TBL] [Abstract][Full Text] [Related]
11. A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence.
Yang CP; Verdier-Pinard P; Wang F; Lippaine-Horvath E; He L; Li D; Höfle G; Ojima I; Orr GA; Horwitz SB
Mol Cancer Ther; 2005 Jun; 4(6):987-95. PubMed ID: 15956256
[TBL] [Abstract][Full Text] [Related]
12. Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization.
Dumontet C; Jaffrezou JP; Tsuchiya E; Duran GE; Chen KG; Derry WB; Wilson L; Jordan MA; Sikic BI
Bull Cancer; 2004 May; 91(5):E81-112. PubMed ID: 15568225
[TBL] [Abstract][Full Text] [Related]
13. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.
Wang Y; O'Brate A; Zhou W; Giannakakou P
Cell Cycle; 2005 Dec; 4(12):1847-53. PubMed ID: 16294009
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
Tripathi S; Srivastava G; Sharma A
Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604
[TBL] [Abstract][Full Text] [Related]
15. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel resistance in cells with reduced beta-tubulin.
Wang Y; Cabral F
Biochim Biophys Acta; 2005 Jun; 1744(2):245-55. PubMed ID: 15950754
[TBL] [Abstract][Full Text] [Related]
17. Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.
Hari M; Wang Y; Veeraraghavan S; Cabral F
Mol Cancer Ther; 2003 Jul; 2(7):597-605. PubMed ID: 12883031
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics.
Galmarini CM; Kamath K; Vanier-Viornery A; Hervieu V; Peiller E; Falette N; Puisieux A; Ann Jordan M; Dumontet C
Br J Cancer; 2003 Jun; 88(11):1793-9. PubMed ID: 12771997
[TBL] [Abstract][Full Text] [Related]
19. LIM-kinase 2, a regulator of actin dynamics, is involved in mitotic spindle integrity and sensitivity to microtubule-destabilizing drugs.
Po'uha ST; Shum MS; Goebel A; Bernard O; Kavallaris M
Oncogene; 2010 Jan; 29(4):597-607. PubMed ID: 19881550
[TBL] [Abstract][Full Text] [Related]
20. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions.
Verrills NM; Flemming CL; Liu M; Ivery MT; Cobon GS; Norris MD; Haber M; Kavallaris M
Chem Biol; 2003 Jul; 10(7):597-607. PubMed ID: 12890533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
